Why Is Xiidra Recalled? Understanding the 2022 FDA Class III Action
•
4 min read
In June 2022, Novartis Pharmaceuticals initiated a voluntary recall of dozens of lots of the prescription dry eye medication Xiidra (lifitegrast ophthalmic solution) after it was discovered they failed to meet specifications for impurities/degradation. The U.S. Food and Drug Administration (FDA) designated this action as a Class III recall, indicating that use of the affected product was not likely to cause harm.
